MetaCap

Kiora Pharmaceuticals Inc. (KPRX)

NASDAQ: KPRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.7202-0.1008 (-12.28%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

KPRX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.72
52-week range
0.72 – 2.91
Day range
0.7202 – 0.8155
Volume / Avg
64.69K / 35.23K
Beta
—

52-week range

$0.72$2.91

KPRX stock today

Shares of Kiora Pharmaceuticals (KPRX) finished lower on Nov 20 at $0.7202, a drop of 12.28% or $0.1008 per share, versus the S&P 500's 3.70% decline. Shares are 75.3% below their 52-week high of $2.91, set on Apr 8, 2026 and 0.0% above the 52-week low of $0.72, near the bottom of the past year's range. KPRX is down 63.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 61.5%.

Kiora Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$2.72), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Kiora Pharmaceuticals

Company profile

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Brian M. Strem Ph.D.
Headquarters
Encinitas, CA
Employees
13

Financial highlights

Full financials

In fiscal 2025, Kiora Pharmaceuticals generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2021. Kiora Pharmaceuticals reported a net loss of $10.8 million, compared with net income of $3.6 million a year earlier. Diluted earnings per share came in at -$2.64, down from $0.87.

Kiora Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$16.02M$0—$0
Growth-100.00%———-100.00%
Net income$-10.84M$3.59M$-12.51M$-13.58M$-13.77M
EPS (diluted)$-2.64$0.87$-24.25$-18.55$-57.12

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$12.00+1566.20%

  • Strong buy 1
  • Buy 0
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.28 vs —

KPRX news

All KPRX news

Kiora Pharmaceuticals peers

Health Care sector
KPRX peer companies
CompanyPrice% ChgMarket capCompare
NRSNNeuroSense Therapeutics Ltd.1.28+1.59%$3.19Mvs KPRX
MDCXMedicus Pharma Ltd.1.14-2.16%$3.16Mvs KPRX
AZTRAzitra Inc0.5168-2.75%$3.13Mvs KPRX
APREAprea Therapeutics Inc.0.229-53.56%$3.25Mvs KPRX
GELSGelteq Limited0.2701-3.74%$3.11Mvs KPRX
SKYESkye Bioscience Inc.0.70-11.03%$3.10Mvs KPRX
XBIOXenetic Biosciences Inc.1.40-9.09%$3.28Mvs KPRX
JAGXJaguar Health Inc.0.227-30.58%$3.03Mvs KPRX

Indexes, lists and sector

Kiora Pharmaceuticals stock FAQ

What is Kiora Pharmaceuticals's stock price today?

KPRX last traded at $0.7202 as of Nov 20, 4:00 PM EST, down 12.28% on the day. Prices are delayed at least 15 minutes.

Does Kiora Pharmaceuticals pay a dividend?

No. Kiora Pharmaceuticals does not currently pay a regular cash dividend.

Who is Kiora Pharmaceuticals's CEO?

Dr. Brian M. Strem Ph.D. is the chief executive officer of Kiora Pharmaceuticals Inc., which has about 13 employees.

Has KPRX ever split its stock?

Yes. The most recent KPRX stock split was a 1-for-9 split on Jun 11, 2024, one of 3 splits on record.

What is the KPRX 52-week high?

The 52-week high for KPRX is $2.91 and the 52-week low is $0.72. The stock is currently 75.3% below its high.

Compare KPRX